These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 23986882)

  • 1. Tumor-penetrating peptides.
    Teesalu T; Sugahara KN; Ruoslahti E
    Front Oncol; 2013; 3():216. PubMed ID: 23986882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor penetrating peptides for improved drug delivery.
    Ruoslahti E
    Adv Drug Deliv Rev; 2017 Feb; 110-111():3-12. PubMed ID: 27040947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo design of a tumor-penetrating peptide.
    Alberici L; Roth L; Sugahara KN; Agemy L; Kotamraju VR; Teesalu T; Bordignon C; Traversari C; Rizzardi GP; Ruoslahti E
    Cancer Res; 2013 Jan; 73(2):804-12. PubMed ID: 23151901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers.
    Zuo H
    J Oncol; 2019; 2019():9367845. PubMed ID: 31346334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transtumoral targeting enabled by a novel neuropilin-binding peptide.
    Roth L; Agemy L; Kotamraju VR; Braun G; Teesalu T; Sugahara KN; Hamzah J; Ruoslahti E
    Oncogene; 2012 Aug; 31(33):3754-63. PubMed ID: 22179825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposed CendR Domain in Homing Peptide Yields Skin-Targeted Therapeutic in Epidermolysis Bullosa.
    Pemmari T; Ivanova L; May U; Lingasamy P; Tobi A; Pasternack A; Prince S; Ritvos O; Makkapati S; Teesalu T; Cairo MS; Järvinen TAH; Liao Y
    Mol Ther; 2020 Aug; 28(8):1833-1845. PubMed ID: 32497513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis.
    Qian J; Zhou S; Lin P; Lei J; Zheng S; Xu W; Wang Y; Gao Z; Yang J
    Drug Dev Res; 2023 Jun; 84(4):654-670. PubMed ID: 36959702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-penetrating delivery of compounds and nanoparticles into tumors.
    Sugahara KN; Teesalu T; Karmali PP; Kotamraju VR; Agemy L; Girard OM; Hanahan D; Mattrey RF; Ruoslahti E
    Cancer Cell; 2009 Dec; 16(6):510-20. PubMed ID: 19962669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protease-activated CendR peptides targeting tenascin-C: mitigating off-target tissue accumulation.
    Tobi A; Haugas M; Rabi K; Sethi J; Põšnograjeva K; Paiste P; Jagomäe T; Pleiko K; Lingasamy P; Teesalu T
    Drug Deliv Transl Res; 2024 Oct; 14(10):2945-2961. PubMed ID: 39012578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urokinase-controlled tumor penetrating peptide.
    Braun GB; Sugahara KN; Yu OM; Kotamraju VR; Mölder T; Lowy AM; Ruoslahti E; Teesalu T
    J Control Release; 2016 Jun; 232():188-95. PubMed ID: 27106816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-penetrating iRGD peptide inhibits metastasis.
    Sugahara KN; Braun GB; de Mendoza TH; Kotamraju VR; French RP; Lowy AM; Teesalu T; Ruoslahti E
    Mol Cancer Ther; 2015 Jan; 14(1):120-8. PubMed ID: 25392370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.
    Teesalu T; Sugahara KN; Kotamraju VR; Ruoslahti E
    Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16157-62. PubMed ID: 19805273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homing Peptides for Cancer Therapy.
    Lingasamy P; Teesalu T
    Adv Exp Med Biol; 2021; 1295():29-48. PubMed ID: 33543454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.
    Simón-Gracia L; Hunt H; Scodeller P; Gaitzsch J; Kotamraju VR; Sugahara KN; Tammik O; Ruoslahti E; Battaglia G; Teesalu T
    Biomaterials; 2016 Oct; 104():247-57. PubMed ID: 27472162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging.
    Cho HJ; Lee SJ; Park SJ; Paik CH; Lee SM; Kim S; Lee YS
    J Control Release; 2016 Sep; 237():177-184. PubMed ID: 27349354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin Fc-Fused Peptide without C-Terminal Arg or Lys Residue Augments Neuropilin-1-Dependent Tumor Vascular Permeability.
    Baek DS; Kim JH; Kim YJ; Kim YS
    Mol Pharm; 2018 Feb; 15(2):394-402. PubMed ID: 29232521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
    Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
    Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
    Hu C; Huang Y; Chen Y
    Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability.
    Pang HB; Braun GB; Friman T; Aza-Blanc P; Ruidiaz ME; Sugahara KN; Teesalu T; Ruoslahti E
    Nat Commun; 2014 Oct; 5():4904. PubMed ID: 25277522
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.